Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of MEDI3902 for prevention of nosocomial pneumonia caused by Pseudomonas aeruginosa in mechanically ventilated patients
2015-001706-34Phase 2Completed
- Sponsor
- MedImmune
- Start
- Dec 2015
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hospital-acquired pneumonia (HAP) and Pseudomonal infection comparing MEDI3902 with Placebo (2 arms). Primary endpoint: Incidence of nosocomial pneumonia caused by Pseudomonas aeruginosa. Started Dec 2015; status: completed.
02
Drugs
gremubamab
03
Conditions
hospital-acquired pneumonia (HAP)Pseudomonal infection
Beyond the preview
Go deeper on 2015-001706-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001706-34.